Back to top

LACOG | Breast Cancer Group

Representatives

Dr. Henry Gomez
Chair
INEN – Instituto Nacional de Enfermedades Neoplásicas

Dr. Max Senna Mano
Vice-chair
Hospital Sírio-Libanês

Dr. Cynthia Mayté Villareal Garza
Secretary
Centro de Cáncer de Mama – TecSalud Instituto Nacional de Cancerología

Steering Committee

Brazil
Dr. Carlos Barrios
HSL PUCRS
Porto Alegre

Dr. Carlos Sampaio
Clínica AMO
Salvador

Dr. Gustavo Werutsky
Latin American Cooperative Oncology Group (LACOG)
Porto Alegre

Dr. Pedro Liedke
Hospital de Clinicas de Porto Alegre (HCPA)
Porto Alegre

Dr. Sergio Simon
Centro Paulista de Oncologia
São Paulo

Uruguay
Dr. Carlos Garbino
Societe Internacional de Senologie
Montevideo

Chile
Jorge Madrid
Centro de Cáncer UC
Santiago

Argentina
Jose Zarba
Centro San Roque
Tucumán

Mexico
Laura Torrecillas
CMN 20 de Noviembre ISSSTE
México DF

Guatemala
William Campbell
Clínicas Herrera Llerandi
Guatemala DF

Venezuela
Dr. Zulay Pastrán
Policlínica Metropolitana/Hospital Dr. Domingo Luciani
Caracas

North America
Otto Metzger Filho
Dana-Farber Cancer Institute
Boston, US

Europe
Dr. Fatima Cardoso
Champalimaud Cancer Center
Lisboa, Portugal

Dr. Juan de la Haba
Grupo Español de Investigación en Cáncer de Mama (GEICAN)
Madrid, Spain

LACOG | Breast Cancer Group

Ongoing studies

GBECAM 0115 – AMAZONA III | Prospective evaluation of breast cancer at Brazilian institutions – Project AMAZONA III

 

LACOG 0413 – Male Breast Cancer | Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study. 

 

LACOG 0419 – NEOSAMBA | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

 

LACOG 0615 – LATINABreast | A study to observe patients characteristics, treatment patterns and outcomes in patients with newly diagnosed breast cancer in Latin America.

 

LACOG 0715 – PALLAS | A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer 

 

LACOG 1020 – GLORIA | The GLORIA Study: A Phase 3, Randomized, Open-label Study Of The Anti-globo H Vaccine Adagloxad Simolenin (Obi-822)/Obi-821 In The Adjuvant Treatment Of Patients With High-risk,Early-stage Globo H-positive Triple Negative Breast Cancer

 

LACOG 2118 – ALEXANDRA/IMpassion 030 | A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.

LACOG | Breast Cancer Group

Closed studies

LACOG 0111 – MGH | MGH – International Breast Cancer Collaborative Project: Determination of an Endocrine Responsive Metastatic Breast Cancer Signature.

 

LACOG 0115 – LORELEI | A Phase II Randomized, Double-Blind, Parallel Cohort Study of Neoadjuvant Letrozole + GDC-0032 versus Letrozole + Placebo in Post-Menopausal Women with ER+/HER2- Primary Breast Cancer.

 

LACOG 0312 – METASTATIC BC | Metastatic breast cancer in Brazil: characterization of patients and treatments.

 

LACOG 0414 | Evaluation of the attitude of premenopausal patients with breast cancer to the risk of loss of fertility caused by chemotherapy.

 

LACOG 0801 – GLICO | A randomized open-label, phase II study of lapatinib/capecitabine or lapatinib/vinorelbine or lapatinib/gemcitabine in subjects with Her2/neu amplified metastatic breast cancer patients progressing after taxanes treatment.

LACOG | Breast Cancer Group

Publications

LACOG | Breast Cancer Group

News